Vesalius Biocapital
Vesalius Biocapital Partners S.à r.l., founded in 2007 and based in Strassen, Luxembourg, is a venture capital and private equity firm focused on investing in life sciences and novel food applications. The firm targets all stages of development, including seed, early, mid, and late-stage ventures, with a particular emphasis on healthcare, pharmaceuticals, therapeutics, medtech, biotechnology, and nanotechnology. Vesalius Biocapital seeks to support companies that develop innovative drugs, medical devices, and diagnostics addressing unmet medical needs, as well as novel nutrition technologies for disease prevention and treatment. The firm primarily invests in Europe, concentrating on the Benelux countries, German-speaking regions, and Scandinavia, typically committing between €1 million and €5 million in each portfolio company, with the possibility of increasing this amount in subsequent rounds. Vesalius Biocapital usually takes minority equity stakes and plays an active role by leading or co-leading investment syndicates and securing board representation in its portfolio companies. With over €150 million under management across two funds, Vesalius has contributed to the development of 20 companies since its inception.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Trod Medical S.A. is a medical equipment and surgical device manufacturer founded in 2006, with headquarters in Leuven, Belgium, and a presence in the Tampa Bay area, USA. The company specializes in developing innovative ablation technologies, particularly focusing on radiofrequency (RF) ablation devices. Trod Medical's flagship product, the EncageTM, is a disruptive percutaneous RF device that enables precise tissue ablation, significantly reducing collateral damage—a critical concern in treatments for conditions such as prostate cancer. With prostate cancer being one of the most prevalent cancers, affecting approximately 240,000 new patients annually in the United States, Trod Medical's technology addresses the limitations of conventional treatments that often lead to severe side effects, including erectile dysfunction and urinary incontinence. The company aims to enhance patient outcomes through its advanced medical devices designed for the focal ablation of soft tissues.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Private Equity Round in 2012
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.